ZYPITAMAG
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZYPITAMAG (ZYPITAMAG).
ZYPITAMAG (pitavastatin magnesium) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to reduced intracellular cholesterol and upregulation of LDL receptors.
| Metabolism | Primarily hepatic via glucuronidation (major) and CYP2C9 (minor); not significantly metabolized by CYP3A4. |
| Excretion | Primarily renal (93% as unchanged pitavastatin and metabolites) via active tubular secretion; fecal (5%) |
| Half-life | Terminal elimination half-life: 12 hours (range 10-14 h) in healthy subjects; supports once-daily dosing |
| Protein binding | >99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Mean Vd: 0.5 L/kg (approx 35 L in 70 kg adult); indicates distribution primarily into extracellular fluid and tissues |
| Bioavailability | Oral bioavailability: 51% (absolute); absorption increased with food (no significant effect on AUC) |
| Onset of Action | Oral: onset of LDL-C reduction observed within 1 week of daily dosing; maximal effect by 4 weeks |
| Duration of Action | Duration of LDL-C reduction persists with continued daily dosing; steady-state achieved in 4-5 days; lipid effects maintained over 24-hour dosing interval |
| Molecular Weight | 476.55 |
2-4 mg orally once daily, at any time of day, with or without food.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Avoid use in severe renal impairment (CrCl <30 mL/min) or in patients on hemodialysis. |
| Liver impairment | Contraindicated in active liver disease or unexplained persistent elevations of hepatic transaminases. No specific Child-Pugh-based adjustments; use caution in patients with mild hepatic impairment. |
| Pediatric use | Not approved for use in pediatric patients. Safety and efficacy in children have not been established. |
| Geriatric use | No specific dose adjustment required; use the standard adult dose. Monitor for adverse effects, as elderly patients may be more susceptible to myopathy. |
| 1st trimester | Contraindicated due to risk of fetal harm; animal studies show teratogenicity and human data suggest potential for congenital anomalies. |
| 2nd trimester | Contraindicated; no adequate studies in pregnant women, and animal studies indicate adverse fetal effects. |
| 3rd trimester | Contraindicated; may cause fetal skeletal muscle toxicity and interfere with fetal lipid metabolism. |
Clinical note
Comprehensive clinical and safety monograph for ZYPITAMAG (ZYPITAMAG).
| Placental transfer | Evidence from animal studies indicates placental transfer; human data limited but expected. |
| Breastfeeding | Excretion into human milk is unknown; potential for serious adverse reactions in nursing infants. Use is not recommended. |
| Lactation Rating |
■ FDA Black Box Warning
Increases in HbA1c and fasting serum glucose levels have been reported; no explicit boxed warning exists.
| Serious Effects |
Hypersensitivity to ZYPITAMAG or any componentActive liver disease or unexplained persistent elevations in serum transaminasesConcomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, boceprevir, telaprevir, clarithromycin, nefazodone, ritonavir, saquinavir, telithromycin, voriconazole)Concomitant use with gemfibrozilPregnancyLactation
| Precautions | Skeletal muscle effects: rhabdomyolysis with renal dysfunction; discontinue if markedly elevated CPK or myopathy suspected, Hepatic effects: persistent elevations in serum transaminases; perform liver function tests before initiation and thereafter as clinically indicated, Endocrine effects: increases in HbA1c and fasting glucose; may require adjustment of hypoglycemic therapy |
| Food/Dietary | No significant food interactions, but avoid excessive alcohol consumption. Grapefruit/grapefruit juice may modestly increase pitavastatin levels (not clinically significant, but caution advised). |
Loading safety data…
| Avoid |
| Teratogenic Risk | Zypitamag (pitavastatin) is contraindicated in pregnancy. Statins are associated with fetal harm due to inhibition of HMG-CoA reductase, essential for cholesterol synthesis. First trimester exposure may increase risk of congenital anomalies (e.g., CNS, limb defects). Second and third trimester exposure risks include fetal growth restriction, low birth weight, and potential developmental toxicity. Pregnancy category: X (FDA). |
| Fetal Monitoring | Monitor hepatic function tests (ALT, AST) periodically due to risk of hepatotoxicity. Assess lipid profile to evaluate therapeutic efficacy. In cases of accidental exposure during pregnancy, perform fetal ultrasound to evaluate for congenital anomalies. Monitor maternal creatine kinase if muscle symptoms occur. No specific fetal monitoring is routinely recommended for statin use in pregnancy as it is contraindicated. |
| Fertility Effects | No definitive human studies on fertility. Animal studies showed no significant impairment of fertility at clinically relevant doses. Statins may theoretically affect steroid hormone synthesis, but clinical relevance is uncertain. In males, possible effects on sperm parameters have not been rigorously studied. Advise patients of unknown risks and discuss alternative therapies if fertility is a concern. |
| Clinical Pearls | ZYPITAMAG (pitavastatin) is a potent statin with minimal CYP metabolism, reducing drug-drug interactions. Monitor for myopathy; increased risk with fibrates or niacin. Start at 2 mg; max 4 mg daily. Do not exceed 1 mg in severe renal impairment (CrCl <30 mL/min). |
| Patient Advice | Take at the same time each day without regard to meals. · Avoid grapefruit and grapefruit juice as they may increase side effects. · Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or dark urine. · Do not take if pregnant or breastfeeding; use effective contraception. · Inform healthcare provider of all medications, especially other cholesterol-lowering drugs, antifungals, or HIV medications. |